
Tamam Bakchoul

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5648969/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants. Clinical Infectious Diseases, 2023, 76, e240-e249.	5.8	11
2	Multicentre evaluation of 5B9, a monoclonal antiâ€PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2022, 20, 252-259.	3.8	5
3	Antibodyâ€mediated procoagulant platelet formation in COVIDâ€19 is AKT dependent. Journal of Thrombosis and Haemostasis, 2022, 20, 387-398.	3.8	18
4	Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19. Blood Advances, 2022, 6, 248-258.	5.2	19
5	Immune-Mediated Platelet Activation in COVID-19 and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Frontiers in Immunology, 2022, 13, 837629.	4.8	14
6	Diagnosis of Platelet Function Disorders: A Challenge for Laboratories. Hamostaseologie, 2022, 42, 036-045.	1.9	5
7	Assessment and Monitoring of Coagulation in Patients with COVID-19: A Review of Current Literature. Hamostaseologie, 2022, 42, 409-419.	1.9	3
8	Antiâ€₽F4 testing for vaccineâ€induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. Journal of Thrombosis and Haemostasis, 2022, 20, 1875-1879.	3.8	6
9	The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood, 2022, 139, 3430-3438.	1.4	19
10	SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nature Immunology, 2021, 22, 74-85.	14.5	490
11	Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood, 2021, 137, 1061-1071.	1.4	162
12	Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. MSphere, 2021, 6, .	2.9	19
13	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nature Communications, 2021, 12, 1152.	12.8	71
14	Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. Journal of Clinical Medicine, 2021, 10, 789.	2.4	38
15	Antibodyâ€mediated platelet activation in COVIDâ€19: A coincidence or a new mechanism of the dysregulated coagulation system?. Journal of Thrombosis and Haemostasis, 2021, 19, 1171-1173.	3.8	6
16	Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica, 2021, 106, 2170-2179.	3.5	101
17	Recommendations for the clinical and laboratory diagnosis of VITT against COVIDâ€19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 1585-1588.	3.8	127
18	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nature Communications, 2021, 12, 3109.	12.8	118

Тамам Вакснои

#	Article	IF	CITATIONS
19	The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood, 2021, 138, 992-996.	1.4	37
20	Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2080-2096.	2.4	21
21	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. Journal of Thrombosis and Haemostasis, 2021, 19, 2094-2095.	3.8	4
22	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 2082-2088.	3.8	14
23	No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 385, 1334-1336.	27.0	19
24	Blood donorâ€derived buffy coat to produce platelets in vitro. Vox Sanguinis, 2020, 115, 94-102.	1.5	3
25	Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan. Haematologica, 2020, 106, 196-207.	3.5	38
26	Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 622-625.	1.3	13
27	Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2020, 196, 400-403.	1.7	5
28	Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. Blood Advances, 2020, 4, 3368-3377.	5.2	11
29	Red blood cell-derived semaphorin 7A promotes thrombo-inflammation in myocardial ischemia-reperfusion injury through platelet GPIb. Nature Communications, 2020, 11, 1315.	12.8	39
30	Feasibility of precise and reliable glucose quantification in human whole blood samples by 1 tesla benchtop NMR. NMR in Biomedicine, 2020, 33, e4358.	2.8	3
31	Heparin-induced thrombocytopenia: Diagnostic challenges in intensive care patients especially with extracorporeal circulation. Thrombosis Research, 2020, 188, 52-60.	1.7	11
32	Beta-Glycerophosphate-Induced ORAI1 Expression and Store Operated Ca2+ Entry in Megakaryocytes. Scientific Reports, 2020, 10, 1728.	3.3	9
33	Apoptosis Inhibition: A Promising Approach for Cold Storage of Apheresis Platelet Concentrates. Hamostaseologie, 2020, 40, .	1.9	Ο
34	Flow Cytometric Assessment of AKT Signaling in Platelet Activation: An Alternative Diagnostic Tool for Small Volumes of Blood. Hamostaseologie, 2020, 40, .	1.9	0
35	Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis. Hamostaseologie, 2019, 39, 227-237.	1.9	26
36	Evaluation of a flow cytometer-based functional assay using platelet-rich plasma in the diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2019, 180, 55-61.	1.7	10

Тамам Вакснои

#	Article	IF	CITATIONS
37	Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia. Haematologica, 2019, 104, 1237-1243.	3.5	26
38	Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates. Haematologica, 2019, 104, 207-214.	3.5	37
39	Maternal <scp>HPA</scp> â€l a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. Vox Sanguinis, 2019, 114, 79-94.	1.5	33
40	Screening and evaluation of potential recipients and donors for living donor uterus transplantation: results from a single-center observational study. Fertility and Sterility, 2019, 111, 186-193.	1.0	29
41	An international external quality assessment for laboratory diagnosis of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 525-531.	3.8	23
42	Autoantibody Mediated Desialylation Impairs Human Thrombopoiesis and Platelet Life Span. Blood, 2019, 134, 2346-2346.	1.4	1
43	Drug-associated thrombocytopenia. Hematology American Society of Hematology Education Program, 2018, 2018, 576-583.	2.5	75
44	Anti-Glycoprotein V Autoantibodies in Patients with Immune Thrombocytopenia: Regularly Detectable and Functionally Relevant. Blood, 2018, 132, 1141-1141.	1.4	0
45	Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding. Blood, 2018, 132, 4717-4717.	1.4	1
46	Evaluation of a diagnostic algorithm for Heparin-Induced Thrombocytopenia. Thrombosis Research, 2017, 152, 77-81.	1.7	7
47	Thrombozytenzerstörung bei ITP. Hamostaseologie, 2016, 36, 187-194.	1.9	10
48	Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2016, 116, 823-834.	3.4	41
49	Heparin-induced thrombocytopenia in 2017 and beyond. Thrombosis and Haemostasis, 2016, 116, 781-782.	3.4	5
50	Assessment of human platelet survival in the NOD/SCID mouse model: technical considerations. Transfusion, 2016, 56, 1370-1376.	1.6	9
51	Safe bridging to warfarin in heparin-induced thrombocytopenia. Thrombosis Research, 2016, 144, 226-228.	1.7	0
52	Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1517-1524.	2.4	79
53	An update on heparin-induced thrombocytopenia: diagnosis and management. Expert Opinion on Drug Safety, 2016, 15, 787-797.	2.4	10
54	Multicentric validation of a rapid assay for heparin-induced thrombocytopenia with different specimen types. Blood Coagulation and Fibrinolysis, 2014, 25, 6-9.	1.0	9

Тамам Вакснои

#	Article	IF	CITATIONS
55	Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. Transfusion, 2014, 54, 640-645.	1.6	34
56	Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thrombosis Research, 2013, 131, e85-e90.	1.7	69
57	The implementation of surface plasmon resonance technique in monitoring pregnancies with expected fetal and neonatal alloimmune thrombocytopenia. Transfusion, 2013, 53, 2078-2085.	1.6	17
58	Anti–protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood, 2013, 121, 2821-2827.	1.4	64
59	Glycosylation of autoantibodies: Insights into the mechanisms of immune thrombocytopenia. Thrombosis and Haemostasis, 2013, 110, 1259-1266.	3.4	19
60	Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thrombosis Research, 2011, 127, 345-348.	1.7	45
61	Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thrombosis and Haemostasis, 2011, 106, 1197-1202.	3.4	44
62	Lowâ€avidity antiâ€HPAâ€1 a alloantibodies are capable of antigenâ€positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. Transfusion, 2011, 51, 2455-2461.	1.6	36
63	GP IIb/Iiia-Dependent Complement Activation Is Common In Patients with Immune Thrombocytopenic Purpura Blood, 2010, 116, 1430-1430.	1.4	0
64	Rapid detection of HPA-1 alloantibodies by platelet antigens immobilized onto microbeads. Transfusion, 2007, 47, 1363-1368.	1.6	20
65	Acquired immune thrombocytopenia: an update on pathophysiology, diagnosis and management. Annals of Blood, 0, 3, 45-45.	0.4	1